ATG5 and ovarian cancer: Indeed recent data have shown that MT-stabilizing drug Paclitaxel, which is used to treat a wide spectrum of tumors, including breast and ovarian cancer, causes dysregulation of BDNF signaling53 accompanied by memory dysfunctions in mice54 and humans55, akin to the loss of ATG5 reported here.